Table 1.

Numbers contributed, by study

Study	Total participants	Cancers			Noncancers
		Noncarriers (N)	Carriers (N)	Prevalence (%)	Noncarriers (N)	Carriers (N)	Prevalence (%)
Tier 1
CAPS	267	168	5	2.89	94	0	0.00
CeRePP	347	295	2	0.67	49	1	2.00
FHCRC	370	259	5	1.89	105	1	0.94
Finland	291	212	3	1.40	76	0	0.00
Germany	318	188	3	1.57	127	0	0.00
ICR	3350	1990	22	1.09	1336	2	0.15
JHU	186	98	1	1.01	87	0	0.00
MAYO	971	386	5	1.28	577	3	0.52
MCCS	1313	1258	16	1.26	39	0	0.00
MD_Anderson	449	–	–	–	448	1	0.22
Porto	479	476	3	0.63	–	–	–
TASPRAC	26	18	0	0.00	8	0	0.00
UTAH	546	147	0	0.00	399	0	0.00
All	8913	5495	65	1.17	3345	8	0.24
Tier 2
CAPS	267	166	7	4.05	86	8	8.51
CeRePP	347	272	25	8.42	48	2	4.00
FHCRC	370	243	21	7.95	96	10	9.43
Finland	291	206	9	4.19	76	0	0.00
Germany	318	174	17	8.90	117	10	7.87
ICR	3350	1896	116	5.77	1278	60	4.48
JHU	186	85	14	14.14	83	4	4.60
MAYO	971	368	23	5.88	556	24	4.14
MCCS	1313	1199	75	5.89	38	1	2.56
MD_Anderson	449	–	–	–	438	11	2.45
Porto	479	407	72	15.03	–	–	–
TASPRAC	26	14	4	22.22	7	1	12.50
UTAH	546	143	4	2.72	395	4	1.00
All	8913	5173	387	6.96	3218	135	4.03
Tier 1 + 2
CAPS	267	161	12	6.94	86	8	8.51
CeRePP	347	270	27	9.09	47	3	6.00
FHCRC	370	238	26	9.85	95	11	10.38
Finland	291	203	12	5.58	76	0	0.00
Germany	318	171	20	10.47	117	10	7.87
ICR	3350	1875	137	6.81	1276	62	4.63
JHU	186	84	15	15.15	83	4	4.60
MAYO	971	363	28	7.16	553	27	4.66
MCCS	1313	1185	89	6.99	38	1	2.56
MD_Anderson	449	–	–	–	437	12	2.67
Porto	479	405	74	15.45	–	–	–
TASPRAC	26	14	4	22.22	7	1	12.50
UTAH	546	143	4	2.72	395	4	1.00
All	8913	5112	448	8.06	3210	143	4.26